ILB-3103

ILB-3103 is a preclinical-stage bispecific antibody-drug conjugate (BsADC) being developed by Innolake Biopharm for the treatment of oncology. As a bispecific ADC, the molecule is engineered to bind simultaneously to two different antigens or epitopes on tumor cells, which can improve binding specificity and promote efficient internalization of the drug-linker complex. Once internalized, the cytotoxic payload is released to induce cell death. This next-generation ADC approach aims to provide a wider therapeutic window and address heterogeneity in tumor antigen expression. The specific molecular targets and payload chemistry of ILB-3103 have not been publicly disclosed by the developer.